ASH Clinical News ACN_5.4s_March_supplement_web | Page 24
Nuclear export
dysregulation is
stealing the cell’s
valuable anti-tumor
defenses 1
IT’S ONE OF THE GREATEST HEISTS IN
CANCER, AND NO ONE SAW IT COMING.
Dysregulated nuclear export has been secretly depleting
the nucleus of key anti-oncogenic proteins, allowing the
tumor to proliferate and survive. 1,2
Investigate the evidence at NuclearExport.com
References: 1. Gupta A, Saltarski JM, White MA, Scaglioni PP, Gerber DE. Therapeutic targeting of nuclear export inhibition
in lung cancer. J Thorac Oncol. 2017;12(9):1446-1450. 2. Sun Q, Chen X, Zhou Q, Burstein E, Yang S, Jia D. Inhibiting cancer
cell hallmark features through nuclear export inhibition. Signal Transduct Target Ther. 2016;1:16010.
Karyopharm and the logo designs presented in this material are registered trademarks of Karyopharm Therapeutics.
Karyopharm Therapeutics | 85 Wells Ave, Newton, MA 02459
© 2018 Karyopharm Therapeutics. All rights reserved. US-NON-09/18-00004